Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Feb. 13, 2015, 79 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $127.50 to $7,830,617.50.

Highlighted Stocks Traded by Insiders:

Silgan Holdings (SLGN) - FREE Research Report

Macdonald Sarah T., who is President - Silgan Plastics at Silgan Holdings, sold 3,768 shares at $57.24 on Feb. 13, 2015. Following this transaction, the President - Silgan Plastics owned 19,898 shares meaning that the stake was reduced by 15.92% with the 3,768-share transaction.

The shares most recently traded at $56.89, down $0.35, or 0.62% since the insider transaction. Historical insider transactions for Silgan Holdings go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 3,768
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 3,768
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 3,768

The average volume for Silgan Holdings has been 234,500 shares per day over the past 30 days. Silgan Holdings has a market cap of $3.6 billion and is part of the consumer goods sector and consumer non-durables industry. Shares are up 6.06% year-to-date as of the close of trading on Friday.

Silgan Holdings Inc., together with its subsidiaries, manufactures and sells rigid packaging for shelf-stable food and other consumer goods products worldwide. The company operates through three segments: Metal Containers, Closures, and Plastic Containers. The stock currently has a dividend yield of 1.06%. The company has a P/E ratio of 17.9. Currently, there are no analysts who rate Silgan Holdings a buy, 1 analyst rates it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SLGN - FREE

TheStreet Quant Ratings

rates Silgan Holdings as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, good cash flow from operations, solid stock price performance and increase in net income. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full

Silgan Holdings Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

NxStage Medical (NXTM) - FREE Research Report

Turk Joseph E Jr, who is President at NxStage Medical, sold 1,500 shares at $17.56 on Feb. 13, 2015. Following this transaction, the President owned 112,575 shares meaning that the stake was reduced by 1.31% with the 1,500-share transaction.

The shares most recently traded at $17.55, down $0.01, or 0.06% since the insider transaction. Historical insider transactions for NxStage Medical go as follows:

  • 4-Week # shares bought: 10,150
  • 4-Week # shares sold: 2,500
  • 12-Week # shares bought: 10,150
  • 12-Week # shares sold: 16,500
  • 24-Week # shares bought: 10,150
  • 24-Week # shares sold: 46,897

The average volume for NxStage Medical has been 383,800 shares per day over the past 30 days. NxStage Medical has a market cap of $1.1 billion and is part of the health care sector and health services industry. Shares are down 2.06% year-to-date as of the close of trading on Friday.

NxStage Medical, Inc., a medical device company, develops, manufactures, and markets products for the treatment of kidney failure, fluid overload, and related blood treatments and procedures. Currently, there are 4 analysts who rate NxStage Medical a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on NXTM - FREE

TheStreet Quant Ratings

rates NxStage Medical as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. Get the full

NxStage Medical Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Misonix (MSON) - FREE Research Report

Gildea John, who is Director at Misonix, bought 15,000 shares at $5.87 on Feb. 13, 2015. Following this transaction, the Director owned 15,000 shares meaning that the stake was boosted by 100% with the 15,000-share transaction.

The shares most recently traded at $12.82, up $6.95, or 54.21% since the insider transaction. Historical insider transactions for Misonix go as follows:

  • 4-Week # shares bought: 30,000
  • 4-Week # shares sold: 8,775
  • 12-Week # shares bought: 30,000
  • 12-Week # shares sold: 8,775
  • 24-Week # shares bought: 32,500
  • 24-Week # shares sold: 35,194

The average volume for Misonix has been 25,700 shares per day over the past 30 days. Misonix has a market cap of $95.2 million and is part of the health care sector and health services industry. Shares are up 0.81% year-to-date as of the close of trading on Friday.

Misonix, Inc., a surgical device company, designs, develops, manufactures, and markets minimally invasive ultrasonic surgical device products for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical applications. The company has a P/E ratio of 33.7. Currently, there are no analysts who rate Misonix a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MSON - FREE

TheStreet Quant Ratings

rates Misonix as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and impressive record of earnings per share growth. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

Misonix Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null